Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Reports New Phase 3 Obexelimab Data in IgG4-Related Disease

Positive Impact 3 of 5 other Written later

Zenas BioPharma announced on October 12, 2026 new data from its Phase 3 INDIGO trial of obexelimab in IgG4-related disease, presented at the 6th International Symposium on IgG4-Related Disease. The filing includes open-label extension flare and safety results, a glucocorticoid toxicity analysis, and initial vaccine response findings, which the company says add to the clinical evidence for obexelimab.

Key points

  • Estimated 12-month probability of remaining flare-free was 0.93 (adjudicated flares) and 0.87 (investigator-determined flares), with five patients pending adjudication.
  • Obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference -11.4; p=0.021).
  • In a vaccine sub-study, 6 of 7 (86%) participants reached influenza seroimmunity and 4 of 4 (100%) reached COVID-19 seroimmunity during a treatment-free window.
  • Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus has topline results expected in 4Q 2026.

The filing

CompanyZenas BioPharma, Inc. (ZBIO)
Form8-K, current report
Filed with the SECOct 13, 2026, 6:01 AM ET
Accession number0001104659-26-115151

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:46 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 13, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.